NCT06976476

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Prospective Randomized Phase II Study Evaluating Efficacy and Safety of IgPro20 as Infection Prophylaxis in Patients With Multiple Myeloma and Hypogammaglobulinemia Receiving Therapy With a Bispecific Monoclonal Antibody (BsAbs)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

Conditions

• Multiple Myeloma
• Hypogammaglobulinemia
• Hypogammaglobulinemia, Acquired

Interventions

Type	Name	Description
DRUG	IgPro20	Will be administered in addition to Standard of Care treatment. IgPro20 is intended for subcutaneous administration using an infusion pump

Timeline

• Start date: 2025-05-08
• Primary completion: 2029-05-08
• Completion: 2029-05-08
• First posted: 2025-05-16
• Last updated: 2026-03-11

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study